Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL93722 | 0.82 | LMNA (0.64) | LMNAALDH1A1THRBOR51E2TDP1 | |
| Glycerin SCHEMBL4554867 | 0.82 | LMNA (0.64) | LMNAALDH1A1THRBOR51E2TDP1 | |
| Glycerin SCHEMBL1831824 | 0.82 | LMNA (0.64) | LMNAALDH1A1THRBOR51E2TDP1 | |
| Glycerin SCHEMBL1685690 | 0.79 | LMNA (0.60) | LMNAALDH1A1THRBOR51E2TDP1 | |
| Glycerin SCHEMBL8151443 | 0.79 | LMNA (0.60) | LMNAALDH1A1THRBOR51E2TDP1 | |
| Glycerin SCHEMBL15061 | 0.79 | LMNA (0.60) | LMNAALDH1A1THRBOR51E2TDP1 | |
| Butanedione SCHEMBL2913079 | 0.79 | LMNA (0.60) | LMNAALDH1A1THRBOR51E2TDP1 | |
| Glycerin SCHEMBL1685695 | 0.79 | LMNA (0.60) | LMNAALDH1A1THRBOR51E2TDP1 | |
| Glycerin SCHEMBL203757 | 0.79 | LMNA (0.60) | LMNAALDH1A1THRBOR51E2TDP1 | |
| Glycerin SCHEMBL1685689 | 0.79 | LMNA (0.60) | LMNAALDH1A1THRBOR51E2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-207439571-U | A kind of temperature sensor for including long-period gratings | 武汉长进激光技术有限公司 | 2018-06-01 | — | — | CN | claimed |
| CN-207439571-U | A kind of temperature sensor for including long-period gratings | 武汉长进激光技术有限公司 | 2018-06-01 | — | — | CN | disclosed |
| US-8449863-B2 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8128906-B2 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8128905-B2 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110177169-A1 | OPHTHALMIC FORMULATIONS OF REVERSED LIQUID CRYSTALLINE PHASE MATERIALS AND METHODS OF USING | EYEON THERAPEUTICS, INC. | 2011-07-21 | — | — | US | disclosed |
| WO-2011006079-A2 | OPHTHALMIC FORMULATIONS OF REVERSED LIQUID CRYSTALLINE PHASE MATERIALS AND METHODS OF USING | LYOTROPOIC THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| EP-2264126-A2 | Drug-delivery vehicles based on reversed liquid crystalline phase materials | Lyotropic Therapeutics, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-1677730-B1 | DRUG-DELIVERY VEHICLES BASED ON REVERSED LIQUID CRYSTALLINE PHASE MATERIALS | LYOTROPIC THERAPEUTICS INC (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100303717-A1 | Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials Cross Reference to Related Applications | ANDERSON DAVID | 2010-12-02 | — | — | US | disclosed |
| US-20100303718-A1 | Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials | ANDERSON DAVID | 2010-12-02 | — | — | US | disclosed |
| US-20100183502-A1 | Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials | ANDERSON DAVID | 2010-07-22 | — | — | US | disclosed |
| US-7713440-B2 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1677730-A4 | DRUG-DELIVERY VEHICLES BASED ON REVERSED LIQUID CRYSTALLINE PHASE MATERIALS | LYOTROPIC THERAPEUTICS INC (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1677730-A2 | DRUG-DELIVERY VEHICLES BASED ON REVERSED LIQUID CRYSTALLINE PHASE MATERIALS | Lyotropic Therapeutics, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005034872-A2 | DRUG-DELIVERY VEHICLES BASED ON REVERSED LIQUID CRYSTALLINE PHASE MATERIALS | LYOTROPIC THERAPEUTICS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050077497-A1 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. | 2005-04-14 | — | — | US | disclosed |